Dr. Yardley on Current Recommendations for ER+ Breast Cancer Treatment

Denise A. Yardley, MD
Published: Wednesday, Oct 25, 2017



Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

The recommendations for adjuvant endocrine therapy are still evolving and utilizes tamoxifen with premenopausal patients. The recent data with axillary dissection with access minimized (ADAM), adjuvant tamoxifen longer against shorter (ATLAS), and extending the therapy from tamoxifen from 5 to 10 years are consistent.

Oncologists are currently tailoring adjuvant endocrine therapy to each patient. Additionally, there have been mixed results from clinical trials, such as the MA17R and the NSABP-42 studies.


Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

The recommendations for adjuvant endocrine therapy are still evolving and utilizes tamoxifen with premenopausal patients. The recent data with axillary dissection with access minimized (ADAM), adjuvant tamoxifen longer against shorter (ATLAS), and extending the therapy from tamoxifen from 5 to 10 years are consistent.

Oncologists are currently tailoring adjuvant endocrine therapy to each patient. Additionally, there have been mixed results from clinical trials, such as the MA17R and the NSABP-42 studies.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x